For more than a decade, the Sabin PDP collaborated with partners from across the globe to develop new, low-cost vaccines that have little commercial market for diseases that primarily impact the world's poorest populations, including humanhookworm, schistosomiasis, onchocerciasis, SARS and Chagas disease. Baylor College of Medicine and Texas Children’s Hospital Center for Vaccine Development continue this research as of May 2017.

Through a recent award obtained by Baylor College of Medicine, the Sabin Vaccine Institute Product Development Partnership (Sabin PDP) will collaborate as part of a consortiom with key partners at the New York Blood CenterUniversity of Texas Medical BranchImmune Design Corporation and Walter Reed Army Institute of Research, in the development of a new vaccine to prevent severe acute respiratory syndrome (SARS). The product development processes for the prototype vaccine are being developed at the Sabin Vaccine Institute and Texas Children’s Hospital Center for Vaccine Development.